PL2982982T3 - Sposób badania przesiewowego związków przy użyciu błonowego STIM1 - Google Patents

Sposób badania przesiewowego związków przy użyciu błonowego STIM1

Info

Publication number
PL2982982T3
PL2982982T3 PL14290232T PL14290232T PL2982982T3 PL 2982982 T3 PL2982982 T3 PL 2982982T3 PL 14290232 T PL14290232 T PL 14290232T PL 14290232 T PL14290232 T PL 14290232T PL 2982982 T3 PL2982982 T3 PL 2982982T3
Authority
PL
Poland
Prior art keywords
screening
compounds
membrane stim1
stim1
membrane
Prior art date
Application number
PL14290232T
Other languages
English (en)
Inventor
Yves Renaudineau
Olivier Mignen
Miguel Burgos
Jacques Olivier Pers
Tinhinane Fali
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Inst Nat Sante Rech Med
Univ De Bretagne Occidentale U B O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Inst Nat Sante Rech Med, Univ De Bretagne Occidentale U B O filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of PL2982982T3 publication Critical patent/PL2982982T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL14290232T 2014-08-06 2014-08-06 Sposób badania przesiewowego związków przy użyciu błonowego STIM1 PL2982982T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1

Publications (1)

Publication Number Publication Date
PL2982982T3 true PL2982982T3 (pl) 2018-03-30

Family

ID=51398585

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14290232T PL2982982T3 (pl) 2014-08-06 2014-08-06 Sposób badania przesiewowego związków przy użyciu błonowego STIM1

Country Status (11)

Country Link
US (2) US20170219588A1 (pl)
EP (2) EP2982982B1 (pl)
JP (2) JP6754751B2 (pl)
CN (2) CN110051836B (pl)
CA (1) CA2952159C (pl)
DK (1) DK2982982T3 (pl)
ES (1) ES2654674T3 (pl)
NO (1) NO2982982T3 (pl)
PL (1) PL2982982T3 (pl)
PT (1) PT2982982T (pl)
WO (1) WO2016020274A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3714942A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
US20240083990A1 (en) * 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148108A1 (en) * 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
JP5559049B2 (ja) * 2007-07-10 2014-07-23 チルドレンズ メディカル センター コーポレーション 間質相互作用分子ノックアウトマウス及びその使用
US20110136123A1 (en) * 2007-08-15 2011-06-09 Universite De Sherbrooke Alternative splicing gene variants in cancer
KR101257550B1 (ko) * 2007-09-10 2013-04-24 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
CN102433383B (zh) * 2011-12-19 2015-07-08 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Also Published As

Publication number Publication date
CN106716130B (zh) 2019-03-29
CN106716130A (zh) 2017-05-24
NO2982982T3 (pl) 2018-03-03
JP2019214576A (ja) 2019-12-19
CN110051836B (zh) 2023-05-26
US20190154690A1 (en) 2019-05-23
CA2952159A1 (en) 2016-02-11
EP2982982A1 (en) 2016-02-10
CA2952159C (en) 2022-08-30
EP3177929A1 (en) 2017-06-14
EP3177929B1 (en) 2018-05-09
ES2654674T3 (es) 2018-02-14
EP2982982B1 (en) 2017-10-04
JP2017531164A (ja) 2017-10-19
US20170219588A1 (en) 2017-08-03
DK2982982T3 (en) 2018-01-08
CN110051836A (zh) 2019-07-26
JP6754751B2 (ja) 2020-09-16
WO2016020274A1 (en) 2016-02-11
PT2982982T (pt) 2018-01-03
JP6861246B2 (ja) 2021-04-21

Similar Documents

Publication Publication Date Title
HK1252413A1 (zh) 培養阿克曼氏菌的方法
IL248850A0 (en) Waste sorting method
ZA201700880B (en) Polymorphs of selinexor
SG11201609204XA (en) Method of producing organic compounds
SG11201703178YA (en) Method for ketonisation of biological material
GB201403096D0 (en) Sample preparation method
GB201402318D0 (en) Method for materials analysis
IL248200A0 (en) Improved instruments for the separation of biological materials
GB2522719B (en) Method of manufacture
IL248697A0 (en) Methods for purifying antibodies
GB201403432D0 (en) Improved method for synthesis of composite membranes
GB201904142D0 (en) Improved method of FT-IMS
SG10201607279RA (en) Method for characterizing material by analysis of speckles
HK1215565A1 (zh) 有機固體材料新型純化方法
GB2522663B (en) A method of selecting a region of interest
PL2982982T3 (pl) Sposób badania przesiewowego związków przy użyciu błonowego STIM1
GB2522716B (en) Method of manufacture
ZA201702798B (en) Method of coalescing a substance
SG11201706066RA (en) Method of producing substance
GB2522904B (en) Method of making an airdam
GB201522618D0 (en) Methods of screening
GB201803781D0 (en) Method for preparation of research organisms
AU2015905320A0 (en) Method of screening
GB201416951D0 (en) Method of synthesis
GB201509021D0 (en) Methods of screening